Training in HIV/AIDS Prevention and Treatment Research in Botswana

博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训

基本信息

  • 批准号:
    9975952
  • 负责人:
  • 金额:
    $ 30.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-01 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

PROJECT ABSTRACT The focus for this proposal is research training for people from Botswana in relation to the various uses of ART for prevention and treatment in the modern era of the HIV epidemic. Recent advancements in coverage strategies and antiretroviral combinations within the Botswana national ART program offer a unique environment for use of modern HIV treatment, safety, and prevention research for the developing world, with a host of research opportunities for training researchers in Botswana, to match current research activities of the faculty mentors and key partners at the Botswana site. The in-country institution for this proposal is the Harvard T.H. Chan School of Public Health, and our LMIC partner for training is the Botswana Harvard AIDS Institute Partnership (BHP), a limited liability nonprofit corporation (LLC) with the Ministry of Health (MOH) in Botswana. BHP is the largest HIV/AIDS research organization in Botswana, and one of the largest in Africa. The long-term goals and objectives of this training program are to train research leaders for BHP, the University of Botswana, and the MOH. Botswana currently has one of the highest prevalence rates of HIV in the world (22%), but has also had the highest rate of antiretroviral drug treatment (ART) for patients with HIV (about 90%) in Africa. The government of Botswana currently operates the most advanced HIV treatment program in Africa, using a universal test-and-treat strategy. The training faculty at Harvard and BHP will focus on how “modern” ART impacts treatment outcomes, safety, and prevention research. HIV-related courses, seminars, and workshops are available for trainees. We have requested funds for 2 predoctoral and 3 postdoctoral positions each year. We estimate that we will train about 18 trainees over 5 years, allowing for multiple years for each PhD candidate and some postdoctoral fellows, and assuming several short-term trainees could fill a single annual training slot. Stipends will be based on current degrees and research experience; thus an MD on an MS or PhD program would be eligible for a postdoctoral-level stipend. Each trainee will have a principal advisor and a faculty advisory committee. Selection of trainees is based on previous academic performance, references, experience, and assurance that the candidates will return to participate in HIV research in Botswana. The quality of the program will be monitored by a Training Advisory Committee composed of experts from the US and from developing countries. The success of the training program will be judged by the relative increase in senior research positions at BHP, UB, and MOH that are individuals who were trained by this program after the second and fourth years. Success will also be judged by the implementation of successful prevention research programs that involve trainees, numbers of trainee publications in high-impact journals, and number of staff positions filled by former trainees at the BHP and the Ministry of Health.
项目摘要 这项建议的重点是对博茨瓦纳人进行与ART的各种用途有关的研究培训 在艾滋病毒流行的现代用于预防和治疗。覆盖范围的最新进展 博茨瓦纳国家抗逆转录病毒方案中的策略和抗逆转录病毒组合提供了独特的 发展中世界使用现代艾滋病毒治疗、安全和预防研究的环境, 为在博茨瓦纳培训研究人员提供大量研究机会,以配合博茨瓦纳目前的研究活动 博茨瓦纳网站的教师导师和主要合作伙伴。这项提案的国内机构是 哈佛大学公共卫生学院,我们的LMIC培训合作伙伴是博茨瓦纳哈佛艾滋病 研究所伙伴关系(BHP),一家有限责任非营利公司(LLC),与卫生部(MOH) 博茨瓦纳。必和必拓是博茨瓦纳最大的艾滋病毒/艾滋病研究机构,也是非洲最大的研究机构之一。 该培训计划的长期目标和目的是为必和必拓培养研究领导者, 博茨瓦纳大学和卫生部。博茨瓦纳目前是#年艾滋病毒感染率最高的国家之一。 世界(22%),但也是艾滋病毒患者抗逆转录病毒药物治疗(ART)比率最高的国家 (约90%)在非洲。博茨瓦纳政府目前正在进行最先进的艾滋病毒治疗。 计划在非洲,使用普遍的测试和治疗战略。哈佛和必和必拓的培训人员将专注于 关于“现代”抗逆转录病毒疗法如何影响治疗结果、安全性和预防研究。 培训人员可参加与艾滋病毒有关的课程、研讨会和讲习班。我们已为%2申请资金 每年博士后和博士后职位各3个。我们估计我们将培训约18名5岁以上的学员 几年,允许每个博士后候选人和一些博士后研究员有好几年的时间,并假设 几名短期实习生可以填补一个年度培训名额。津贴将以当前学位为基础。 和研究经验;因此,攻读硕士或博士学位的博士有资格攻读博士后学位 津贴。每名学员将有一名首席顾问和一个教职员工咨询委员会。实习生的遴选是 根据以前的学业成绩、推荐信、经验和对应聘者 回国参加博茨瓦纳的艾滋病毒研究。该计划的质量将通过培训进行监督 由美国和发展中国家的专家组成的咨询委员会。的成功之路 培训计划将根据必和必拓、UB和卫生部高级研究职位的相对增加情况进行评判 是指在第二年和第四年后接受该计划培训的个人。成功也将是 从涉及受训者的成功预防研究方案的实施情况来看, 在影响较大的期刊上发表见习文章,以及必和必拓前见习生填补的工作人员职位数量 和卫生部。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHAHIN LOCKMAN其他文献

SHAHIN LOCKMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHAHIN LOCKMAN', 18)}}的其他基金

Addressing Major HIV Prevention and Health Outcomes Questions in an Era of Universal ART: Mentoring in a Community-Randomized Trial
解决普遍抗逆转录病毒治疗时代的主要艾滋病毒预防和健康结果问题:社区随机试验中的指导
  • 批准号:
    10112810
  • 财政年份:
    2017
  • 资助金额:
    $ 30.06万
  • 项目类别:
Mentoring in Global Patient-Oriented HIV Research in the Era of COVID-19 and Universal ART
COVID-19 和通用 ART 时代全球以患者为导向的艾滋病毒研究的指导
  • 批准号:
    10483694
  • 财政年份:
    2017
  • 资助金额:
    $ 30.06万
  • 项目类别:
Mentoring in Global Patient-Oriented HIV Research in the Era of COVID-19 and Universal ART
COVID-19 和通用 ART 时代全球以患者为导向的艾滋病毒研究的指导
  • 批准号:
    10669765
  • 财政年份:
    2017
  • 资助金额:
    $ 30.06万
  • 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
  • 批准号:
    9073896
  • 财政年份:
    2015
  • 资助金额:
    $ 30.06万
  • 项目类别:
Training in HIV Genomics, Treatment, and Cure Research in Botswana
博茨瓦纳的艾滋病毒基因组学、治疗和治愈研究培训
  • 批准号:
    10688707
  • 财政年份:
    2013
  • 资助金额:
    $ 30.06万
  • 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
  • 批准号:
    10396618
  • 财政年份:
    2013
  • 资助金额:
    $ 30.06万
  • 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
  • 批准号:
    10161878
  • 财政年份:
    2013
  • 资助金额:
    $ 30.06万
  • 项目类别:
Training in HIV/AIDS Prevention and Treatment Research in Botswana
博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训
  • 批准号:
    10462051
  • 财政年份:
    2013
  • 资助金额:
    $ 30.06万
  • 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
  • 批准号:
    8316378
  • 财政年份:
    2010
  • 资助金额:
    $ 30.06万
  • 项目类别:
Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in Botswana
博茨瓦纳艾滋病毒暴露婴儿的短期母乳喂养和复方新诺明
  • 批准号:
    8144267
  • 财政年份:
    2010
  • 资助金额:
    $ 30.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了